Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Global variations in the burden of SARS-CoV-2 infection and its outcomes in pregnant women by geographical region and country's income status: a meta-analysis.
Sheikh J, Lawson H, Allotey J, Yap M, Balaji R, Kew T, Stallings E, Coomar D, Gaetano-Gil A, Zamora J, Thangaratinam S; PregCOV-19 Living Systematic Review Consortium. Sheikh J, et al. BMJ Glob Health. 2022 Nov;7(11):e010060. doi: 10.1136/bmjgh-2022-010060. BMJ Glob Health. 2022. PMID: 36368768 Free PMC article.
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk; RECOVERY Collaborative Group. RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk, et al. Lancet. 2023 May 6;401(10387):1499-1507. doi: 10.1016/S0140-6736(23)00510-X. Epub 2023 Apr 13. Lancet. 2023. PMID: 37060915 Free PMC article. Clinical Trial.
Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe.
Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C; Tuberculosis Network European Trials group; Adamides T, Akkerman O, Andersen AB, Bakos Á, Bjarnason A, Bruchfeld J, Chesov D, Codecasa LR, Cirillo D, Danilovits M, Davidavičienė E, Duarte R, De Souza Galvão ML, Garnier S, Gjocaj M, Günther G, Ibraim E, Kappnik M, Khachatryan N, Klimuk D, Kuksa L, Jachym MF, Josefsdottir K, Kaluzhenina A, Lange C, Mack U, Makek MJ, Manika K, Mclaughlin AM, Mema D, Mengshoel AT, Muylle I, Nanovic Z, Özkara Ş, Perl S, Pesut D, Pierdou D, Ryskulov G, Skowroński M, Solovic I, Sukholytka M, Svetina P, Terleeva Y, Tiberi S, Togonidze T, Torri S, Turaev L, Usmanova R, Wirtz G, Vasankari T, Zhdanova E. Günther G, et al. Among authors: tiberi s. Clin Microbiol Infect. 2024 Mar 13:S1198-743X(24)00121-6. doi: 10.1016/j.cmi.2024.03.009. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38490355
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
Diacon AH, Barry CE 3rd, Carlton A, Chen RY, Davies M, de Jager V, Fletcher K, Koh GCKW, Kontsevaya I, Heyckendorf J, Lange C, Reimann M, Penman SL, Scott R, Maher-Edwards G, Tiberi S, Vlasakakis G, Upton CM, Aguirre DB. Diacon AH, et al. Among authors: tiberi s. Nat Med. 2024 Mar;30(3):896-904. doi: 10.1038/s41591-024-02829-7. Epub 2024 Feb 16. Nat Med. 2024. PMID: 38365949 Free PMC article. Clinical Trial.
Standards for clinical trials for treating TB.
du Cros P, Greig J, Alffenaar JC, Cross GB, Cousins C, Berry C, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm JT, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh KP, Motta I, Lange C, Seddon JA, Nyang'wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh CR, Dheda K, Marais BJ. du Cros P, et al. Among authors: tiberi s. Int J Tuberc Lung Dis. 2023 Dec 1;27(12):885-898. doi: 10.5588/ijtld.23.0341. Int J Tuberc Lung Dis. 2023. PMID: 38042969 Free PMC article.
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort.
Global Tuberculosis Network and TB/COVID-19 Global Study Group; Casco N, Jorge AL, Palmero DJ, Alffenaar JW, Fox GJ, Ezz W, Cho JG, Denholm J, Skrahina A, Solodovnikova V, Arbex MA, Alves T, Rabahi MF, Pereira GR, Sales R, Silva DR, Saffie MM, Salinas NE, Miranda RC, Cisterna C, Concha C, Fernandez I, Villalón C, Vera CG, Tapia PG, Cancino V, Carbonell M, Cruz A, Muñoz E, Muñoz C, Navarro I, Pizarro R, Cristina Sánchez GP, Vergara Riquelme MS, Vilca E, Soto A, Flores X, Garavagno A, Bahamondes MH, Merino LM, Pradenas AM, Revillot ME, Rodriguez P, Salinas AS, Taiba C, Valdés JF, Subiabre JN, Ortega C, Palma S, Castillo PP, Pinto M, Bidegain FR, Venegas M, Yucra E, Li Y, Cruz A, Guelvez B, Victoria Plaza R, Tello Hoyos KY, Cardoso-Landivar J, Van Den Boom M, Andréjak C, Blanc FX, Dourmane S, Froissart A, Izadifar A, Rivière F, Schlemmer F, Manika K, Diallo BD, Hassane-Harouna S, Artiles N, Mejia LA, Gupta N, Ish P, Mishra G, Patel JM, Singla R, Udwadia ZF, Alladio F, Angeli F, Calcagno A, Centis R, Codecasa LR, De Lauretis A, Esposito SMR, Formenti B, Gaviraghi A, Giacomet V, Goletti D, Gualano G, Matteelli A, Migliori GB, Motta I, Palmieri F, Pontali E, Prestileo T, Riccardi N, Sad… See abstract for full author list ➔ Global Tuberculosis Network and TB/COVID-19 Global Study Group, et al. Among authors: tiberi s. Eur Respir J. 2023 Nov 29;62(5):2300925. doi: 10.1183/13993003.00925-2023. Print 2023 Nov. Eur Respir J. 2023. PMID: 37827576 Free PMC article.
216 results